An epidermal growth factor receptor chimeric human-murine monoclonal antibody

被引:216
作者
Harding, J
Burtness, B
机构
[1] Prous Sci, Dept Med Informat, Barcelona 08025, Spain
[2] Yale Univ, New Haven, CT USA
关键词
D O I
10.1358/dot.2005.41.2.882662
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. It is composed of extracellular domains, including a ligand-binding domain, a hydrophobic transmembrane region and a tyrosine kinase-containing cytoplasmic region. Stimulation of the EGFR by enclogenous ligands, EGF or transforming growth factor-alpha (TGF-alpha), results in a conformational change in the receptor, permitting it to enter into dimers and other oligomers. Dimerization results in activation of intracellular tyrosine kinase, protein phosphorylation and stimulation of various cell signaling pathways that mediate gene transcription and cell cycle progression. The EGFR is expressed on normal human cells but higher levels of expression of the receptor have also been shown to be correlated with malignancy in a variety of cancers. In addition, expression of the EGFR by malignant cells is associated with poor prognosis and resistance to therapy.
引用
收藏
页码:107 / 127
页数:21
相关论文
共 85 条
[1]  
ABBRUZZESE JL, 2001, AACR NCI EORTC INT C
[2]  
ARNOLETTI JP, 2004, CASTROENTEROLOGY S2, V126
[3]  
BADARINATH S, 2004, P AM SOC CLIN ONCOL, V23
[4]  
BALIN D, 2004, EUR J CANC S, V2
[5]   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].
Baselga, J ;
Pfister, D ;
Cooper, MR ;
Cohen, R ;
Burtness, B ;
Bos, M ;
D'Andrea, G ;
Seidman, A ;
Norton, L ;
Gunnett, K ;
Falcey, J ;
Anderson, V ;
Waksal, H ;
Mendelsohn, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914
[6]  
Baselga J, 2001, EUR J CANCER, V37, pS16
[7]  
BASELGA J, 2002, P AM SOC CLIN ONCO 1, V21
[8]  
BASELGA J, 2002, P AM ASS CANC RES, V43
[9]   Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results [J].
Baumann, M ;
Krause, M .
RADIOTHERAPY AND ONCOLOGY, 2004, 72 (03) :257-266
[10]  
BENAVENTE S, 2004, P AM ASS CANC RES, V45